PKM2-IN-3 is an inhibitor of PKM2 kinase with an IC 50 value of 4.1 μM. PKM2-IN-3 exhibits an anti-neuroinflammatory effect by inhibiting PKM2-mediated glycolysis and NLRP3 activation.

PKM2-IN-3 (compound 10i) inhibits the TNF-α release of LPS-stimulated RAW264.7 macrophages, with an IC 50 value of 5.2 μM. PKM2-IN-3 exhibits the lowest toxicity with a CC 50 value of 43.6 μM[1]. PKM2-IN-3 (0.1-100 μM; 20 min) inhibits PKM2 kinase activity in a cell-free molecular level with an IC 50 value of 4.1 μM[1].

PKM2-IN-3 (1, 10 mg/kg; i.p.; daily for 3 days ) significantly reverses the LPS-induced mice behavior changes in open field test[1]. PKM2-IN-3 (1, 10 mg/kg; i.v.; injected at 4 hours and 24 hours after ischemia onset) reduces the infarct volume and improves neurological deficits of tMCAO rats[1]. Animal Model: LPS-induced mice (male 6-8 weeks old; 20.0-22.0 g)[1]Dosage: 1, 10 mg/kg Administration: i.p.; daily for 3 days Result: Reversed the LPS-induced mice behavior changes in open field test. Animal Model: tMCAO Sprague-Dawley rats (Male 8-10 weeks old; 250.0-280.0 g)[1]Dosage: 1, 10 mg/kg Administration: i.v.; injected at 4 hours and 24 hours after ischemia onset Result: Reduced the infarct volume and improved neurological deficits of tMCAO rats.

2408841-19-8

C21H22O4

338.4

PKM2-IN-3;PKM2-IN-3

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years